Repeatome drug developer Rome Therapeutics is based on intellectual property from Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai.
US-based drug developer Rome Therapeutics officially launched yesterday with $50m in series A funding to commercialise founding intellectual property from Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai.
The capital was supplied by investors including GV and Partners Innovation Fund, respective vehicles for internet technology group Alphabet and care provider Partners Healthcare. VC firm Arch Venture Partners also contributed cash.
Rome is developing treatments for cancer and autoimmune diseases focused on the repeatome: the term…